CXCR3 and autoimmune thrombocytopenic purpura: Therefore, CXCL11 may be a potential therapeutic target for ITP, since the analogue is that Tizina et al. [30] successively modelled the structural determinants of these interactions of CXCL9/CXCR3, CXCL10/CXCR3 and CXCL11/CXCR3 complexes and their physico-chemical features in order to be used for drug design.